لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Georgiev P; Department of Discovery Oncology, Merck & Co., Inc., Kenilworth, New Jersey., Muise ES; Department of Genome and Biomarker Sciences, Merck & Co., Inc., Kenilworth, New Jersey., Linn DE; Department of Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey., Hinton MC; Department of Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey., Wang Y; Department of Discovery Oncology, Merck & Co., Inc., Kenilworth, New Jersey., Cai M; Department of Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey., Cadzow L; Department of Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey., Wilson DC; Department of Genome and Biomarker Sciences, Merck & Co., Inc., Kenilworth, New Jersey., Sukumar S; Department of Discovery Oncology, Merck & Co., Inc., Kenilworth, New Jersey., Caniga M; Department of Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey., Chen L; Department of Informatics IT, Merck & Co., Inc., Kenilworth, New Jersey., Xiao H; Department of Informatics IT, Merck & Co., Inc., Kenilworth, New Jersey., Yearley JH; Department of Genome and Biomarker Sciences, Merck & Co., Inc., Kenilworth, New Jersey., Sriram V; Department of Discovery Oncology, Merck & Co., Inc., Kenilworth, New Jersey., Nebozhyn M; Department of Genome and Biomarker Sciences, Merck & Co., Inc., Kenilworth, New Jersey., Sathe M; Department of Genome and Biomarker Sciences, Merck & Co., Inc., Kenilworth, New Jersey., Blumenschein WM; Department of Genome and Biomarker Sciences, Merck & Co., Inc., Kenilworth, New Jersey., Kerr KS; Department of Genome and Biomarker Sciences, Merck & Co., Inc., Kenilworth, New Jersey., Hirsch HA; Department of Genome and Biomarker Sciences, Merck & Co., Inc., Kenilworth, New Jersey., Javaid S; Department of Genome and Biomarker Sciences, Merck & Co., Inc., Kenilworth, New Jersey., Olow AK; Department of Genome and Biomarker Sciences, Merck & Co., Inc., Kenilworth, New Jersey., Moy LY; Department of Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey., Chiang DY; Department of Genome and Biomarker Sciences, Merck & Co., Inc., Kenilworth, New Jersey., Loboda A; Department of Genome and Biomarker Sciences, Merck & Co., Inc., Kenilworth, New Jersey., Cristescu R; Department of Genome and Biomarker Sciences, Merck & Co., Inc., Kenilworth, New Jersey., Sadekova S; Department of Discovery Oncology, Merck & Co., Inc., Kenilworth, New Jersey., Long BJ; Department of Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey., McClanahan TK; Department of Genome and Biomarker Sciences, Merck & Co., Inc., Kenilworth, New Jersey., Pinheiro EM; Department of Discovery Oncology, Merck & Co., Inc., Kenilworth, New Jersey.

المصدر: Molecular cancer therapeutics [Mol Cancer Ther] 2022 Mar 01; Vol. 21 (3), pp. 427-439.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE

مواضيع طبية MeSH: B7-H1 Antigen*/antagonists & inhibitors , Immunotherapy* , Neoplasms*/drug therapy , Neoplasms*/genetics , Programmed Cell Death 1 Receptor*/antagonists & inhibitors, Animals ; Biomarkers, Tumor/genetics ; Cell Line, Tumor ; Disease Models, Animal ; Humans ; Immune Checkpoint Inhibitors ; Mice ; Tumor Microenvironment

المؤلفون: Perera SA; Department of Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey. perera.samanthi@gmail.com., Kopinja JE; Department of Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey., Ma Y; Department of Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey., Muise ES; Department of Genetics and Pharmacogenomics, Merck & Co., Inc., Kenilworth, New Jersey., Laskey J; Department of Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey., Chakravarthy K; Department of Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey., Chen Y; Department of Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey., Cui L; Department of Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey., Presland J; Department of Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey., Sathe M; Department of Genetics and Pharmacogenomics, Merck & Co., Inc., Kenilworth, New Jersey., Javaid S; Department of Genetics and Pharmacogenomics, Merck & Co., Inc., Kenilworth, New Jersey., Minnihan EC; Department of Discovery Pharmaceutical Sciences, Merck & Co., Inc., Kenilworth, New Jersey., Ferguson HM; Department of Discovery Pharmaceutical Sciences, Merck & Co., Inc., Kenilworth, New Jersey., Piesvaux J; Department of Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey., Pan BS; Department of Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey., Zhao S; Department of Discovery Oncology, Merck & Co., Inc., Kenilworth, New Jersey., Sharma SK; Department of Discovery Oncology, Merck & Co., Inc., Kenilworth, New Jersey., Woo HC; Department of Pharmacokinetics, Merck & Co., Inc., Kenilworth, New Jersey., Pucci V; Department of Pharmacokinetics, Merck & Co., Inc., Kenilworth, New Jersey., Knemeyer I; Department of Pharmacokinetics, Merck & Co., Inc., Kenilworth, New Jersey., Cemerski S; Department of Discovery Oncology, Merck & Co., Inc., Kenilworth, New Jersey., Cumming J; Department of Discovery Chemistry, Merck & Co., Inc., Kenilworth, New Jersey., Trotter BW; Department of Discovery Chemistry, Merck & Co., Inc., Kenilworth, New Jersey., Tse A; Department of Clinical Research, Merck & Co., Inc., Kenilworth, New Jersey., Khilnani A; Department of Clinical Research, Merck & Co., Inc., Kenilworth, New Jersey., Ranganath S; Department of Discovery Oncology, Merck & Co., Inc., Kenilworth, New Jersey., Long BJ; Department of Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey., Bennett DJ; Department of Discovery Chemistry, Merck & Co., Inc., Kenilworth, New Jersey., Addona GH; Department of Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey.

المصدر: Molecular cancer therapeutics [Mol Cancer Ther] 2022 Feb; Vol. 21 (2), pp. 282-293. Date of Electronic Publication: 2021 Nov 23.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE

مواضيع طبية MeSH: Immunity, Innate/*immunology , Immunotherapy/*methods , Interferons/*metabolism , Neoplasms/*immunology, Animals ; Cell Line, Tumor ; Female ; Humans ; Mice

المؤلفون: Raghavan S; Department of Immunology, Merck & Co., Inc., Palo Alto, CA, United States.; Department of Microbiology and Immunology, Institute for Biomedicine, University of Gothenburg, Gothenburg, Sweden., Tovbis-Shifrin N; Department of Immunology, Merck & Co., Inc., Palo Alto, CA, United States., Kochel C; Department of Immunology, Merck & Co., Inc., Palo Alto, CA, United States., Sawant A; Department of Immunology, Merck & Co., Inc., Palo Alto, CA, United States., Mello M; Centre d'Immunophénomique - CIPHE (PHENOMIN), Aix Marseille Université (UMS3367), National Institute of Health and Medical Research (INSERM) (US012), The French National Centre for Scientific Research (CNRS) (UMS3367), Marseille, France., Sathe M; Department of Immunology, Merck & Co., Inc., Palo Alto, CA, United States., Blumenschein W; Department of Immunology, Merck & Co., Inc., Palo Alto, CA, United States., Muise ES; Merck & Co., Inc., Boston, MA, United States., Chackerian A; Department of Immunology, Merck & Co., Inc., Palo Alto, CA, United States., Pinheiro EM; Merck & Co., Inc., Boston, MA, United States., Rosahl TW; Merck & Co., Inc., Kenilworth, NJ, United States., Luche H; Centre d'Immunophénomique - CIPHE (PHENOMIN), Aix Marseille Université (UMS3367), National Institute of Health and Medical Research (INSERM) (US012), The French National Centre for Scientific Research (CNRS) (UMS3367), Marseille, France., de Waal Malefyt R; Department of Immunology, Merck & Co., Inc., Palo Alto, CA, United States.

المصدر: Frontiers in immunology [Front Immunol] 2021 Nov 29; Vol. 12, pp. 752348. Date of Electronic Publication: 2021 Nov 29 (Print Publication: 2021).

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

مواضيع طبية MeSH: CD8-Positive T-Lymphocytes/*immunology , Lymphocytes, Tumor-Infiltrating/*immunology , Neoplasms, Experimental/*immunology , Programmed Cell Death 1 Receptor/*immunology , T-Lymphocyte Subsets/*immunology, Animals ; CD8-Positive T-Lymphocytes/drug effects ; Female ; Immune Checkpoint Inhibitors/pharmacology ; Lymphocytes, Tumor-Infiltrating/drug effects ; Mice ; Mice, Inbred C57BL ; Mice, Knockout ; Programmed Cell Death 1 Receptor/deficiency

المؤلفون: Singh L; Discovery Oncology, Merck & Co., Inc., Boston, Massachusetts. latika.singh@merck.com., Muise ES; Genetics and Pharmacogenomics, Merck & Co., Inc., Boston, Massachusetts., Bhattacharya A; Immunology, Merck & Co., Inc., Boston, Massachusetts., Grein J; Genetics and Pharmacogenomics, Merck & Co., Inc., South San Francisco, California., Javaid S; Genetics and Pharmacogenomics, Merck & Co., Inc., Boston, Massachusetts., Stivers P; Discovery Oncology, Merck & Co., Inc., Boston, Massachusetts., Zhang J; Immunology, Merck & Co., Inc., Boston, Massachusetts., Qu Y; Immunology, Merck & Co., Inc., Boston, Massachusetts., Joyce-Shaikh B; Discovery Oncology, Merck & Co., Inc., South San Francisco, California., Loboda A; Genetics and Pharmacogenomics, Merck & Co., Inc., Boston, Massachusetts., Zhang C; Genetics and Pharmacogenomics, Merck & Co., Inc., Boston, Massachusetts., Meehl M; Biologics Discovery, Merck & Co., Inc., Boston, Massachusetts., Chiang DY; Genetics and Pharmacogenomics, Merck & Co., Inc., Boston, Massachusetts., Ranganath SH; Discovery Oncology, Merck & Co., Inc., Boston, Massachusetts., Rosenzweig M; Discovery Oncology, Merck & Co., Inc., Boston, Massachusetts., Brandish PE; Discovery Oncology, Merck & Co., Inc., Boston, Massachusetts.

المصدر: Molecular cancer research : MCR [Mol Cancer Res] 2021 Apr; Vol. 19 (4), pp. 702-716. Date of Electronic Publication: 2020 Dec 28.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101150042 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3125 (Electronic) Linking ISSN: 15417786 NLM ISO Abbreviation: Mol Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Melanoma/*immunology , Membrane Glycoproteins/*immunology , Monocytes/*immunology , Myeloid-Derived Suppressor Cells/*immunology , Receptors, Immunologic/*immunology, Animals ; Female ; Heterografts ; Humans ; Melanoma/metabolism ; Membrane Glycoproteins/metabolism ; Mice ; Monocytes/metabolism ; Myeloid-Derived Suppressor Cells/metabolism ; Receptors, Immunologic/metabolism

المؤلفون: Wang Y; Department of Oncology Early Discovery, Merck & Co., Inc., Boston, Massachusetts, USA., Cui L; Department of Quantitative Biosciences, Merck & Co., Inc., Boston, Massachusetts, USA., Georgiev P; Department of Oncology Early Discovery, Merck & Co., Inc., Boston, Massachusetts, USA., Singh L; Department of Oncology Early Discovery, Merck & Co., Inc., Boston, Massachusetts, USA., Zheng Y; Department of Oncology Early Discovery, Merck & Co., Inc., Boston, Massachusetts, USA., Yu Y; Department of Oncology Early Discovery, Merck & Co., Inc., Boston, Massachusetts, USA., Grein J; Department of Genetics and Pharmacogenomics, Merck & Co., Inc., Boston, Massachusetts, USA., Zhang C; Department of Genetics and Pharmacogenomics, Merck & Co., Inc., Boston, Massachusetts, USA., Muise ES; Department of Genetics and Pharmacogenomics, Merck & Co., Inc., Boston, Massachusetts, USA., Sloman DL; Department of Discovery Chemistry, Merck & Co., Inc., Boston, Massachusetts, USA., Ferguson H; Department of Pharmaceutical Science, Merck & Co., Inc., Boston, Massachusetts, USA., Yu H; Department of Pharmaceutical Science, Merck & Co., Inc., Boston, Massachusetts, USA., Pierre CS; Department of Oncology Early Discovery, Merck & Co., Inc., Boston, Massachusetts, USA., Dakle PJ; Department of Oncology Early Discovery, Merck & Co., Inc., Boston, Massachusetts, USA., Pucci V; Department of Pharmacokinetics, Pharmacodynamics & Drug Metabolism, Merck & Co., Inc., Boston, Massachusetts, USA., Baker J; Department of Pharmacokinetics, Pharmacodynamics & Drug Metabolism, Merck & Co., Inc., Boston, Massachusetts, USA., Loboda A; Department of Genetics and Pharmacogenomics, Merck & Co., Inc., Boston, Massachusetts, USA., Linn D; Department of Quantitative Biosciences, Merck & Co., Inc., Boston, Massachusetts, USA., Brynczka C; Dept. Safety and Exploratory Pharmacology, Safety Assessment and Laboratory Animal Resources, Merck & Co., Inc., Boston, Massachusetts, USA., Wilson D; Department of Genetics and Pharmacogenomics, Merck & Co., Inc., Boston, Massachusetts, USA., Haines BB; Department of Quantitative Biosciences, Merck & Co., Inc., Boston, Massachusetts, USA., Long B; Department of Quantitative Biosciences, Merck & Co., Inc., Boston, Massachusetts, USA., Wnek R; Department of Translational Biomarkers, Merck & Co., Inc., Boston, Massachusetts, USA., Sadekova S; Department of Oncology Early Discovery, Merck & Co., Inc., Boston, Massachusetts, USA., Rosenzweig M; Department of Oncology Early Discovery, Merck & Co., Inc., Boston, Massachusetts, USA., Haidle A; Department of Discovery Chemistry, Merck & Co., Inc., Boston, Massachusetts, USA., Han Y; Department of Discovery Chemistry, Merck & Co., Inc., Boston, Massachusetts, USA., Ranganath SH; Department of Oncology Early Discovery, Merck & Co., Inc., Boston, Massachusetts, USA.

المصدر: Oncoimmunology [Oncoimmunology] 2021 Mar 18; Vol. 10 (1), pp. 1896643. Date of Electronic Publication: 2021 Mar 18.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: Electronic Cited Medium: Internet ISSN: 2162-402X (Electronic) Linking ISSN: 21624011 NLM ISO Abbreviation: Oncoimmunology Subsets: MEDLINE

مواضيع طبية MeSH: CD8-Positive T-Lymphocytes* , Receptors, Prostaglandin E, EP4 Subtype*, Animals ; Cyclooxygenase 2 ; Dinoprostone ; Macrophages ; Mice